.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Cantor Fitzgerald
Cerilliant
Baxter
Fish and Richardson
Medtronic
McKinsey
US Department of Justice
UBS
Chinese Patent Office

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,713,938

« Back to Dashboard

Which drugs does patent 7,713,938 protect, and when does it expire?


Patent 7,713,938 protects SYNJARDY XR, GLYXAMBI, JARDIANCE, and SYNJARDY, and is included in four NDAs.

This patent has thirty-six patent family members in thirty countries.

Summary for Patent: 7,713,938

Title:Crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Abstract: The invention relates to a crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.
Inventor(s): Himmelsbach; Frank (Mittelbiberach, DE), Schmid; Sandra (Bad Wurzach, DE), Schuehle; Martin (Oberhoefen, DE), Martin; Hans-Jurgen (Biberach, DE), Eckhardt; Matthias (Biberach, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:11/406,971
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Boehringer IngelheimSYNJARDY XRempagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208658-001Dec 9, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY
Boehringer IngelheimSYNJARDY XRempagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208658-002Dec 9, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY
Boehringer IngelheimSYNJARDY XRempagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208658-003Dec 9, 2016RXYesNo► Subscribe► Subscribe► SubscribeYY
Boehringer IngelheimSYNJARDY XRempagliflozin; metformin hydrochlorideTABLET, EXTENDED RELEASE;ORAL208658-004Dec 9, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY
Boehringer IngelheimGLYXAMBIempagliflozin; linagliptinTABLET;ORAL206073-001Jan 30, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY
Boehringer IngelheimGLYXAMBIempagliflozin; linagliptinTABLET;ORAL206073-002Jan 30, 2015RXYesYes► Subscribe► Subscribe► SubscribeYY
Boehringer IngelheimJARDIANCEempagliflozinTABLET;ORAL204629-001Aug 1, 2014RXYesNo► Subscribe► Subscribe► SubscribeYY
Boehringer IngelheimJARDIANCEempagliflozinTABLET;ORAL204629-002Aug 1, 2014RXYesYes► Subscribe► Subscribe► SubscribeYY
Boehringer IngelheimSYNJARDYempagliflozin; metformin hydrochlorideTABLET;ORAL206111-002Aug 26, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY
Boehringer IngelheimSYNJARDYempagliflozin; metformin hydrochlorideTABLET;ORAL206111-001Aug 26, 2015RXYesNo► Subscribe► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,713,938

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05009669May 3, 2005
05018012Aug 19, 2005

International Patent Family for Patent: 7,713,938

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan2009046513► Subscribe
Japan4226070► Subscribe
Japan2008540373► Subscribe
Israel187087► Subscribe
CroatiaP20100033► Subscribe
European Patent Office1888552► Subscribe
Hong Kong1115133► Subscribe
European Patent Office2166007► Subscribe
Spain2337498► Subscribe
Eurasian Patent Organization013079► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Teva
Fuji
Chubb
AstraZeneca
Chinese Patent Office
Julphar
Daiichi Sankyo
US Army
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot